Lung Cancer

Eric K. Singhi, MD, explains the rationale for evaluating lurbinectedin plus atezolizumab as maintenance therapy after chemotherapy in ES-SCLC.

Panelists discuss how to manage patients who cannot proceed to surgery after neoadjuvant chemoimmunotherapy by pivoting to definitive concurrent chemoradiation with reduced-dose chemotherapy, while emphasizing the need to distinguish true progression from inflammatory changes.

Panelists discuss how real-world data from the Flatiron Health database revealed that surgical completion rates after neoadjuvant therapy are lower in community practice (65%) compared with clinical trials, particularly for patients with poor performance status or more advanced stage disease.

The top 5 OncLive videos of the week cover insights in ovarian cancer, RCC, melanoma, non–small cell lung cancer, and non–muscle-invasive bladder cancer.

The Phase 3 IMforte trial demonstrated that maintenance therapy with lurbinectedin plus atezolizumab was well tolerated and explored a novel approach to extending disease control following first-line treatment in patients with extensive-stage small cell lung cancer.

Sonam Puri, MD, discusses future research directions and ongoing developments in small cell lung cancer.

On May 31, 2025, a select group of US medical and thoracic oncologists from academic and cancer specialty institutions participated in a workshop held in conjunction with the 2025 Annual Meeting of the American Society of Clinical Oncology in Chicago, Illinois. The participants discussed current and emerging therapeutic strategies in treating patients with EGFR-mutant (EGFRm), advanced non–small cell lung cancer (NSCLC). The session was moderated by Helena Yu, MD, who led discussions on managing the balance between improved efficacy outcomes and increased toxicity with combination therapies, and sequencing strategies for first-line and subsequent treatments.

On June 1, 2025, OncLive® convened a group of early career medical oncologists specializing in thoracic malignancies to discuss pivotal abstracts from the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO 2025). The session was moderated by Eric K. Singhi, MD, with faculty providing real-world perspectives on emerging therapies, treatment sequencing challenges, and evolving biomarker strategies. The discussion centered on antibody-drug conjugates (ADCs), targeted therapies for oncogene-driven NSCLC, perioperative treatment approaches, and novel diagnostic tools.

Panelists discuss how surgeons evaluate candidates for neoadjuvant chemoimmunotherapy by emphasizing that all patients with stage II and III disease should be considered regardless of PD-L1 or mutation status, while highlighting the importance of multidisciplinary collaboration in treatment decisions.

Panelists discuss how the CheckMate 77T perioperative trial updates showed that even patients receiving fewer than 4 cycles of neoadjuvant therapy still benefited, and circulating tumor DNA (ctDNA) clearance serves as an independent biomarker for predicting outcomes regardless of pathologic response status.

Tali Azenkot, MD, discusses the rationale for combining dupilumab with cemiplimab in early-stage, resectable non–small cell lung cancer.

Hyein Jeon, MD, highlights key abstracts and takeaways from an OncLive Fellows Forum on lung cancer.

The FDA approved the Oncomine Dx Express Test for tumor profiling and as a companion diagnostic for sunvozertinib in non–small cell lung cancer.

The FDA grants approval to sunvozertinib in NSCLC and linvoseltamab in myeloma and removes REMS requirements for approved CAR T-cell therapies.

David Spigel, MD, discusses the potential clinical effect of a 14-gene molecular assay for identifying candidates for adjuvant chemotherapy in NSCLC.

Lyudmila A. Bazhenova, MD, discusses ways that sunvozertinib expands the treatment paradigm for EGFR-mutated metastatic non–small cell lung cancer.

The FDA has granted accelerated approval to sunvozertinib (Zegfrovy) for locally advanced or metastatic NSCLC harboring EGFR exon 20 insertion mutations.

Chinmay Jani, MD, discusses the rate of inclusion of patient-reported outcome end points in clinical trials of patients with lung cancer.

Here is your guide to all therapeutic options that were cleared by the FDA in June 2025 spanning tumor types.

Experts in the fields of lung, head and neck, HER2+ breast, and hematologic cancers discuss notable updates for fellows from the 2025 AACR Annual Meeting.

Noha Soror, MD, discussed data from an analysis of patient-reported outcomes in from hospitalized patients with cancer.

China’s NMPA approved savolitinib plus osimertinib for EGFR-mutant NSCLC with MET amplification after progression on prior EGFR TKI therapy.

OncLive® showcases 13 cancer care pioneers, who have won the 2025 Giants of Cancer Care award.

The top 5 OncLive videos of the week cover insights in myelofibrosis, lung cancer, ovarian cancer, breast cancer, and melanoma.

The FDA grants approval to Dato-DXd in EGFR+ NSCLC, revumenib sNDA is under priority review for NPM1-mutant AML, and more from OncLive this week.